Neurol. praxi. 2025;26(5):386-390 | DOI: 10.36290/neu.2024.084
Acute polyradiculoneuritis - Guillain-Barré syndrome
- Neurologická klinika FZS Univerzity Pardubice a PKN
GBS is an autoimmune neuropathy and is the most frequent cause of acutely developed flaccid paresis. Infect or an immune impuls precede in 70 %. Molecular mimicry participates in pathogenesis. The illness developes till 4 weeks, but commonly during 2 weeks. In typical cases the GBS begins with hypesthesia and weakness of distal parts of lower etremities and then spreads in ascedent direction. Facial nerve is affected in 50 %. Paresis of ventilatory muscles may be a cause of intubation - in 30 %. Mortality undulates between 3 % and 10 %. After 6 months there are 60-80 % of patients able to walk unsupported. The relapses occure in 2-5 %. Electrophysiological investigation is very important and it defines demyelinating or axonal type of lesion. Clinical findings can be devided in generalized forms, focal forms and Miller-Fisher syndrome.
Keywords: autoimmune neuropathy, demyelination, axonal lesion, electomyography, therapy.
Received: November 12, 2024; Revised: December 9, 2024; Accepted: December 12, 2024; Prepublished online: December 12, 2024; Published: November 6, 2025 Show citation
References
- Almalki S, Alghamdi L, Khayyat J, et al. Characteristics of Patients Diagnosed With Guillain-Barré Syndrome at King Abdulaziz University Hospital, Jeddah, Saudi Arabia, From 2000 to 2018. Cureus. 2023;15(11):e48703. https://doi.org/10.7759/cureus.48703.
Go to original source... 
Go to PubMed... - Busl K, Fried H, Muehlschlegel S, et al. Guidelines for neuroprognostication in adults with Guillain-Barré syndrome. Neurocrit Care. 2023;38:564-583. https://doi.org/10.1007/s12028-023-01707-3. Go to original source... Go to PubMed...
- Censi S, Bisaccia G, Gallina S., et al. Guillain-Barré syndrom and SARS Cov-2 infection: a systematic review and meta-analysis on a debated issue and evidence for the "Italian factor". EJN. 2024;31(2):a16094. https://doi.org/10.1111/ene.16094. Go to original source... Go to PubMed...
- Habib AA, Waheed W. Guillain-Barré syndrome. Continuum (Minn). 2023;29(5):1327-1356. Go to original source...
- Hannaford A, Paling E, Silsby M, et al. Electrodiagnostic studies and new diagnostic modalities for evaluations of peripheral nerve disorders. Muscle Nerve. 2024;69:653-669. DOI: 10.1002/mus.28068. Go to original source... Go to PubMed...
- Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nature Reviews/Neurology. 2019;15(11):671-683. https://doi.org/10.1038/s41582-019-0250-9. Go to original source... Go to PubMed...
- Rajabally YA. Immunoglobulin and monoclonal antibody therapies in Guillain-Barré syndrome. Neurotherapeutics. 2022;19:885-896. https://doi.org/10.1007/s13311-022-01253-4. Go to original source... Go to PubMed...
- Revendová K, Volný O, Junkerová J, et al. Nodo-paranodopatie s protilátkami IgG4 proti neurofascinu 155. Cesk Slov Neurol N. 2021;84(6):567-569. i: https://doi.org/10.48095/cccsnn2021567. Go to original source...
- Shastri A, Ayian AA, Kishore U, et al. Immune-mediated neuropathies: Pathophysiology and management. Int. J. Mol. Sci. 2023;24:7288. https://doi.org/10.3390/ijms24087288. Go to original source... Go to PubMed...
- Van Doorn PA, van den Bergh PYK, Hadden RDM, et al. EAN/PNS guideline on diagnosis and treatment of Guillain-Barré syndrome. EJN. 2023;30(12),3646-3674. https://doi.org/10.1111/ene.16073. Go to original source... Go to PubMed...